Last reviewed · How we verify

NCT05144152: M3-AA

Diagnostic Accuracy of M3 in Predicting Colorectal Advanced Adenoma Recurrence (M3-AA)

Recruiting now Last updated 27 August 2024
What this trial tests

trial testing M3 in Colorectal Adenoma in 600 participants. Currently enrolling.

Timeline
13 December 2021
Primary endpoint
15 December 2024
15 June 2025

Quick facts

Lead sponsorChinese University of Hong Kong
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment600
Start date13 December 2021
Primary completion15 December 2024
Estimated completion15 June 2025
Sites1 location across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, any sex, with Colorectal Adenoma or Advanced Adenoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim to evaluate the diagnostic accuracy of FIT and the novel panel of four bacterial gene markers collectively named as M3, to detect recurrent advanced adenomas in patients with history of colonic adenomas.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Colorectal Adenoma

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05144152.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing